AI Solutions for Drug Development
AI models and applications to identify opportunities and increase efficiency in product development pipelines
Platform · Cloud SaaSCompany source
Company profile
About Labcorp Drug Development
Labcorp Drug Development is a division of Labcorp that provides comprehensive AI and real-world data solutions for the biopharma industry. The company operates at the intersection of diagnostic laboratory services and advanced analytics, offering data-driven insights that span from drug discovery through commercialization. With access to 45 billion diagnostic test results annually from 175 million patient encounters, Labcorp maintains one of the world's most extensive healthcare datasets. Their AI capabilities include predictive analytics for patient recruitment, pharmacokinetics modeling, fraud detection, natural language processing, and optical character recognition tools. The company supports over 5,100 clinical protocols and works with 186,000+ clinical investigator sites worldwide. Their solutions address critical challenges in drug development including protocol design, feasibility analytics, patient identification, and trial optimization. Labcorp's AI-powered platform, developed in partnership with Amazon Web Services (AWS) and Datavant, delivers longitudinal laboratory data with advanced analytics capabilities. The company serves pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) with HIPAA-compliant, de-identified, ethically sourced data. Their therapeutic focus areas include neurology (particularly Alzheimer's disease), immunology, oncology, rare diseases, and cardiovascular conditions. All data solutions maintain regulatory-grade quality standards to support evidence generation for regulatory submissions and market access decisions.
Company description Labcorp Drug Development official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Labcorp Drug Development?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's disease
- cardiovascular disease
- immunology
- NASH
- neurology
- oncology
- rare diseases
Who it serves
- Biotechnology firms
- Contract Research Organizations (CROs)
- Health plans
- Managed care organizations
- Pharmaceutical companies
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Recorded integration context: AWS, Datavant, EHR/claims linkage.
Geographic context
MarketsGlobal (186K+ clinical investigator sites worldwide) · United States
Company sourceOfficial website
Company milestones
Platform expansion
Launched AI-powered real-world data platform for Alzheimer's disease in partnership with AWS and Datavant
Partnerships
Recorded partners
- Amazon Web Services (AWS)
- Datavant
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
AI-Powered Real-World Data Platform for Alzheimer's Disease
Longitudinal laboratory data at scale with advanced analytics for Alzheimer's research
Platform · Cloud SaaSCompany source
Feasibility Analytics Platform
Self-service SaaS analytics for hypothesis validation and RWE exploration
Software · Cloud SaaSCompany source
Gaps in Care Solutions
At-home test collection to efficiently close gaps in care for health plan members
Service · HybridCompany source
Patient Identification Solutions
Alert tool to identify and engage newly diagnosed patients for clinical trials
Software · Cloud SaaSCompany source
Real World Data Solutions
Regulatory-grade real world data transformed into actionable insights for biopharma
Platform · Cloud SaaSCompany source
Trial Optimization Services
Data-driven precision to accelerate clinical trials and reduce risk
Service · HybridCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Comprehensive assessment of cytologist workplace needs and evolving professional landscape.Journal of the American Society of Cytopathology · Jan 1, 2026
The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.British journal of pharmacology · Dec 1, 2025
Assessing the quality and making appropriate use of historical negative control data: A report of the International Workshop on Genotoxicity Testing (IWGT).Environmental and molecular mutagenesis · Dec 1, 2025
In vivo genotoxicity testing strategies: Report from the 8th International Workshop on Genotoxicity Testing (IWGT).Environmental and molecular mutagenesis · Dec 1, 2025
Breast Biomarker Cytology Practice in 2023: Results of a College of American Pathologists Survey.Archives of pathology & laboratory medicine · Dec 1, 2025
Combining Lumipulse p-tau217 and Aβ42/40 as confirmatory tests for Aβ positivity prior to disease-modifying therapy.Alzheimer's & dementia : the journal of the Alzheimer's Association · Sep 1, 2025
Clinical validation
Clinical-trial records
A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy ParticipantsNCT06258174 · Mentioned · COMPLETED
A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy ParticipantsNCT05138653 · Mentioned · COMPLETED
PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.NCT05255276 · Mentioned · COMPLETED
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult SubjectsNCT05158335 · Mentioned · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
60% reduction in pre-research time
Call center benefits verification using AI model
$100,000 savings in first year
Fraud detection model implementation
63% positive identification rate
NASH clinical study patient identification (34 of 54 subjects)
Call Center Client
Applied artificial intelligence to benefits verification model to reduce pre-research time
More than 60% reduction in pre-research time
Fraud Detection Client
Fraud detection model examines flagged orders for irregular patterns
Estimated savings of up to $100,000 in the first year of rollout
NASH Clinical Study
AI predictions informed where to locate new subjects for NASH clinical study
34 out of 54 potential subjects tested positive (63% success rate)
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Labcorp Drug Development
Recent articles published on Labcorp Drug Development's official website.
Gail Bromage
Read on Labcorp Drug DevelopmentBiocompatibility evaluation of implantable medical devices
Read on Labcorp Drug DevelopmentDelivering precision in a critical bone defect model for implantable device safety testing
Read on Labcorp Drug DevelopmentFrom complexity to clarity: Making sense of mosaic variants and preliminary evidence genes
Read on Labcorp Drug DevelopmentBeyond traditional immunoassay: LC-MS for antibody isotyping and quantitation
Read on Labcorp Drug Development07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.